The Efficacy and Safety of Lyoplant® Onlay in Repairing Cerebral Dura Mater

NCT03951272 | Unknown DMC

• 1 other identifier: AAG-G-H-1715
• Study Type: interventional
• Target: 240
• Locations: 1 country
• Sites: 1

Brief Summary

Objective of this clinical trial is to compare the safety and efficacy of Mianfengxing Kexishou Yingmo Bupian(Lyoplant® Onlay) and Yingmo Bupianfor dural repair.270 subjects will be enrolled for this study.

Conditions

Replacement and Extension of Connective Tissue Structure in Neurosurgery

Outcome Measures

Primary Outcomes (1)

• Surgical successful rate without leakage of cerebrospinal fluid (CSF) 90 days

  Surgical successful rate without leakage of cerebrospinal fluid (CSF) 90 days after the surgery (Confirmed by radiological image evaluation and physical examination on surgical site). Each patient firstly undergoes an initial CT and if necessary, MRI will be used to further examine the volume of CSF leakage.

  90days

Study Arms (2)

Lyoplant® Onlay

EXPERIMENTAL

All the model including 2.5cm×2.5cm, 5.0cm×5.0cm,2.5cm×7.5cm,7.5cm×7.5cm,10.0cm×12.5cm will be used in this study

Device: Lyoplant® Onlay/DURAFORM™ Dural Graft Implant

DURAFORM™ Dural Graft Implant

ACTIVE COMPARATOR

All the model including 2.54cm×2.54cm,5.08cm×5.08cm, 2.54cm×7.62cm, 7.62cm×7.62cm,10.16cm×12.70cm will be used in this study

Device: Lyoplant® Onlay/DURAFORM™ Dural Graft Implant

Interventions

Lyoplant® Onlay/DURAFORM™ Dural Graft Implant DEVICE

Lyoplant® Onlay will be used as a dura substitute for the repair of the duramater.The DURAFORM™ Dural Graft Implant will be used in the procedures where the repair or substitution of the patient's dura mater is needed.

DURAFORM™ Dural Graft Implant; Lyoplant® Onlay

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Surgical patients who will receive dura mater replacement in neurosurgery;
• to 75 years old, either sexes;
• Patients are ready and able to accept all visits during the trial.
• Patients are willing and able to sign Informed Consent Form (ICF) to join this clinical trial.
• Related to lesions:
• Target lesion is cerebral and cerebellum dura mater defect closure, intracranial hypertension remission;
• Surgical wound classification is Class I/sterile operation and risk index category (RIC) ≤ 2.

You may not qualify if:

• Patients with local cerebral infection;
• Patients who suffer from systemic infection (e.g. urinary tract infection (UTI), acquired pneumonia) or any infection sign at surgical site before the surgery, with body temperature \> 38.5℃, positive result in blood culture, and/or positive result in chest X-ray examination;
• Patients who are allergic to the equipment components (Such as, by asking the patient's history of allergies, doctors understand whether the patient is allergic to proteins of bovine origin or implant or not);
• There is metal implant in patient's brain and the implant will interfere the assessment on devices or surgery recovery;
• Patients in gestation period or lactation period or planned to be pregnant during the trial;
• Patients with more than 1 separated dura mater defects;
• Patients with previous neurosurgery history at the same anatomic site;
• Patients with cranial open trauma;
• Patients requiring the use of dura adhesive or sealant;
• Patients whose expected survival time is less than 12 months;
• Patients received chemotherapy and/or radiotherapy within 3 months before the surgery;
• Patients who had diagnosed as malignant tumor of other parts except brain tumor, uncontrolled diabetes, septicemia, systemic collagen diseases clinically;
• Patients who had been accompanied with liver and renal dysfunction, with ALT and AST\>1.5 times the upper limit of the standard, total bilirubin level \> 2.5 mg/dl, creatinine level \> 2.0 mg/dl;
• Patients with significant clinical coagulation disorders, Activated partial thromboplastin time (APTT) was 3 times more than ULN (upper limit of normal), international normalized ratio (INR) is ≥ 1.7, or under the treatment of Warfarin or Coumadin;
• Patients with immune system damage or autoimmune diseases (white blood cell (WBC) count is \< 4000/uL or \>20,000/uL);

Sponsors & Collaborators

• B. Braun Medical International Trading Company Ltd.: lead

Study Sites (1)

The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310009, China

RECRUITING

Central Study Contacts

Zongjie Duan

CONTACT

+86 10 57632775; zongjie.duan@bbraun.com

Sally Jin

CONTACT

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 14, 2019
• First Posted: May 15, 2019
• Study Start: July 24, 2018
• Primary Completion: August 30, 2019
• Study Completion: August 30, 2019
• Last Updated: May 15, 2019

Record last verified: 2019-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)